Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.
The earnings yield does not consider the growth of the business. A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Fortis Malar Hospitals's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was -25.07%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
If the P/E ratio is an indication of how many years it takes for the company to earn back the stock price shareholders pay to buy the shares, the earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.
If a company loses money, the earnings yield is negative. This gives a more straightforward indication that the company is losing money. This is an advantage of using earnings yield instead of the P/E ratio in valuation. For valuation purposes, the P/B Ratio and the P/S Ratio should be used for companies that are losing money.
Like the P/E ratio, the earnings yield can be used to compare investments in different industries. It can even be used to compare the attractiveness of different asset classes such as bonds and cash. Of course, the earnings yield should not be the only factor in deciding which asset classes to invest.
Also similar to the P/E ratio, the earnings yield does not consider the growth of the business. A growing company with the same earnings yield should be more attractive than a company that has the same earnings yield but does not grow.
Just like the P/E Ratio, non-recurring items such as selling part of the business, selling a previous investment, etc., can affect earnings yield dramatically. The earning yield is also a poor indication for cyclical companies. When a cyclical stock has a high earnings yield it is usually at the peak of its cycle.
Fortis Malar Hospitals Earnings Yield % Related Terms
Fortis Malar Hospitals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2.220 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Fortis Malar Hospitals (BOM:523696) has a Earnings Yield % of 4.42% as of Jul. 18, 2026. Earnings Yield equals per-share earnings divided by share price. It is the inverse of the price-earnings ratio. View historical data on Fortis Malar Hospitals and its competitors.
Is Fortis Malar Hospitals' Earnings Yield % too high?
Fortis Malar Hospitals' current Earnings Yield % is 4.42%. Overall, Fortis Malar Hospitals has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fortis Malar Hospitals' Earnings Yield % compare to HCA and THC?
Fortis Malar Hospitals' Earnings Yield % of 4.42% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield % for a Healthcare Providers & Services company?
A good Earnings Yield % depends on the Healthcare Providers & Services industry context. However, Earnings Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield % mean?
A high Earnings Yield % can signal that a stock is expensive relative to its fundamentals. Earnings Yield equals per-share earnings divided by share price. It is the inverse of the price-earnings ratio. View historical data on Fortis Malar Hospitals and its competitors. Fortis Malar Hospitals's current Earnings Yield % is 4.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortis Malar Hospitals stock overvalued right now?
Based on GuruFocus' analysis, Fortis Malar Hospitals (BOM:523696) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹0.03, compared to a current price of ₹50.22 — trading 167300% above its estimated fair value. The current Earnings Yield % is 4.42%. Fortis Malar Hospitals' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield % calculated?
Earnings Yield % is calculated from a company's financial statements. For Fortis Malar Hospitals (BOM:523696), the current Earnings Yield % is 4.42% as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fortis Malar Hospitals (BOM:523696) Overvalued in 2026?
Based on GuruFocus' analysis, Fortis Malar Hospitals stock appears to be overvalued.
The current stock price of ₹50.22 is trading 167300% above its estimated GF Value™ of ₹0.03.
GuruFocus considers Fortis Malar Hospitals to be Significantly Overvalued.
Key valuation signals for BOM:523696:
Earnings Yield %: 4.42%
GF Value™: ₹0.03 vs. price of ₹50.22 (167300% above fair value)
No single metric tells the full story. See the BOM:523696 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fortis Malar Hospitals Ltd is an India-based company engaged in the provision of healthcare services. It focuses on providing medical care in the areas of cardiology and cardiac surgery, neurosurgery, gynecology, orthopedics, gastroenterology, neurology, pediatrics, diabetes, nephrology, and internal medicine. The company provides healthcare services in various branches of medicine such as general surgery, general medicine, pediatrics, neurology, cardiology, ophthalmology, radiology, pathology, gastroenterology, urology, thoracic surgery, plastic surgery, and other allied specialties. It operates in one business, namely, in the health care services.
31GF Score
Get the complete analysis for BOM:523696
Earnings Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:523696 has been successfully added to your 
